Study of remestemcel-L with ruxolitinib for severe graft-versus-host disease
Part of Immune system & allergy clinical trials.
This trial tests whether adding remestemcel-L (a type of cell therapy) to the standard drug ruxolitinib can help people with severe graft-versus-host disease (a complication after a stem cell transplant) that hasn't improved with steroids. The goal is to see if it can reduce symptoms and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have severe graft-versus-host disease (GVHD) that hasn't responded to steroid treatment.
- You can take medications by mouth.
- You have adequate blood cell counts (ANC > 1000 and platelets ≥ 20,000).
- You have not had more than 2 doses of ruxolitinib for GVHD before joining.
- You are not on a ventilator or requiring continuous positive pressure ventilation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
This trial tests whether adding etanercept to ruxolitinib works better than ruxolitinib alone for severe graft-versus-host disease (GVHD) that has not responded to steroids. GVHD is a common complication after a stem cell transplant where donor cells attack the patient's body.
This trial studies whether adding cord-blood–derived cells to ruxolitinib can improve steroid-resistant acute graft-versus-host disease (GVHD) affecting the lower gut or liver. It’s meant for people who are not getting better (or are worsening) despite adequate steroid treatment.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
Hear when a new GVHD - Graft-Versus-Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.